CYTK - Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstruc
CYTK - Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales - Click For Release
Story updates
10:20:14 AM UTC
SquawkNews
CYTK Cytokinetics announces MHRA marketing authorisation for myqorzo®▼ (aficamten) and positive guidance from nice for symptomatic obstructive hypertrophic cardiomyopathy in England and Wales
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.